Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.34 USD | +2.36% | +2.41% | -17.35% |
Financials (USD)
Sales 2024 * | 538M | Sales 2025 * | 581M | Capitalization | 1.33B |
---|---|---|---|---|---|
Net income 2024 * | -189M | Net income 2025 * | -203M | EV / Sales 2024 * | 2.59 x |
Net Debt 2024 * | 67.93M | Net Debt 2025 * | 234M | EV / Sales 2025 * | 2.69 x |
P/E ratio 2024 * |
-7.02
x | P/E ratio 2025 * |
-6.73
x | Employees | 1,453 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.26% |
Latest transcript on NovoCure Limited
1 day | +2.36% | ||
1 week | +2.41% | ||
Current month | -21.05% | ||
1 month | -6.59% | ||
3 months | -11.89% | ||
6 months | -12.79% | ||
Current year | -17.35% |
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 62 | 11-08-04 |
David Hung
BRD | Director/Board Member | 66 | 18-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.19% | 18 M€ | +3.04% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 12.34 | +2.36% | 1,317,018 |
24-04-23 | 12.06 | +1.90% | 839,660 |
24-04-22 | 11.83 | -2.15% | 809,482 |
24-04-19 | 12.09 | +0.33% | 850,446 |
24-04-18 | 12.05 | 0.00% | 1,392,284 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.35% | 1.33B | |
+72.58% | 12.34B | |
-18.04% | 7.98B | |
+3.57% | 5.81B | |
+6.65% | 5.04B | |
+20.83% | 4.31B | |
-20.27% | 4.03B | |
-41.19% | 2.21B | |
+0.25% | 1.99B | |
+4.02% | 1.87B |
- Stock Market
- Equities
- NVCR Stock